Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Big Pharma Subdued In Its Response To Trump's Travel EO

Executive Summary

Big pharma has been muted in its response to President Trump's executive order imposing severe travel restrictions on nationals from seven Muslim-majority countries for 90 days. Small biotech, however, has no reservations about speaking out against the so-called 'immigration ban'.

You may also be interested in...

US Visa Concerns Led ICH To Choose Canadian Meeting Site

The US, one of ICH’s original three member authorities, was spurned in favor of Canada for the pharmaceutical regulatory harmonization initiative’s next meeting in the region because of some participants’ difficulties obtaining US visas.

Immigration Ban: BioPharma Response Varies From Silence To Dissent

While PhRMA, BIO and Pfizer had no response to President Trump’s travel order, Allergan and some smaller firms voiced their objections; PhRMA to meet with Trump on Tuesday.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts